What is Freenome?
Headquartered in Brisbane, California, Freenome Holdings, Inc. is at the forefront of the precision medicine revolution. By integrating multiomics—the study of cell-free DNA, RNA, and proteins—with advanced machine learning, the company has developed a proprietary platform capable of detecting cancer at its earliest, most treatable stages. Its SimpleScreen portfolio, which initially focuses on colorectal cancer and advanced adenomas, represents a significant shift toward non-invasive, blood-based diagnostics. By partnering with major health systems and pharmaceutical entities, Freenome is effectively bridging the gap between complex biological data and actionable clinical insights, positioning itself as a critical player in the global oncology landscape.
How much funding has Freenome raised?
Freenome has raised a total of $1.4B across 8 funding rounds:
Series A
$7M
Series B
$160M
Series C
$270M
Series D
$300M
Other Financing Round
$290M
Other Financing Round
$254M
Stock/Share Issuance
$75M
Series A (2017): $7M led by CRV, Section 32, Verily, Andreessen Horowitz, GV, Data Collective, Founders Fund, Anne Wojcicki, and Asset Management
Series B (2019): $160M supported by RA Capital Management, Roceh Venture Fund, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, T. Rowe Price Associates, and BrightEdge Ventures
Series C (2020): $270M featuring Kaiser Permanente Ventures, Andreessen Horowitz, Rock Springs Capital, Section 32, Janus Henderson Investors, RA Capital Management, Colorectal Cancer Alliance, Soleus Capital, T. Rowe Price Associates, GV, Catalio Capital Management, EcoR1 Capital, Novartis, Perceptive Advisors, DCVC, Farallon Capital Management, Sands Capital, BrightEdge Ventures, Polaris Partners, Bain Capital, Cormorant Asset Management, Fidelity Management & Research Company, and Roche
Series D (2021): $300M backed by Perceptive Advisors, a16z Life Sciences Growth Fund, RA Capital Management, Artis Ventures, and BrightEdge Ventures
Other Financing Round (2022): $290M with participation from Roche
Other Financing Round (2024): $254M led by Andreessen Horowitz, Roche, and Ark Investments
Stock/Share Issuance (2025): $75M supported by Roche
Key Investors in Freenome
Roche
A global pioneer in pharmaceuticals and diagnostics, Roche focuses on personalized healthcare and the development of targeted therapies and companion diagnostics.
Andreessen Horowitz
A prominent venture capital firm that invests in both early-stage startups and established growth companies across the technology and life sciences sectors.
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including diagnostics and research tools.
What's next for Freenome?
Following this major strategic investment, Freenome is well-positioned to accelerate the commercialization of its diagnostic pipeline and expand its clinical research partnerships. The company's trajectory, marked by consistent backing from top-tier venture firms and strategic healthcare partners, suggests a focus on scaling its platform for broader clinical adoption. As Freenome continues to refine its AI-driven screening capabilities, the focus will likely shift toward securing regulatory milestones and integrating its technology into standard-of-care protocols, ultimately aiming to reduce the global burden of cancer through early, accessible intervention.
See full Freenome company page
